SCHEMBL1029948

SCHEMBL1029948

CCCCCC(=O)OC1=CCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NAAA Q02083 2/20 0.45
DGKA P23743 1/20 0.44
ALOX15 P16050 1/20 0.43
LMNA P02545 2/20 0.42
PAM P19021 2/20 0.41
MEN1 O00255 2/20 0.41
KDM4E B2RXH2 1/20 0.41
RECQL P46063 1/20 0.41
MAPK1 P28482 2/20 0.40
POLM Q9NP87 1/20 0.40
POLK Q9UBT6 1/20 0.40
POLL Q9UGP5 1/20 0.40
POLH Q9Y253 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PTPN1 P18031 1/20 0.40
NLRP3 Q96P20 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11686307 0.98 KMT2A (0.50) KMT2ASMN1; SMN2NAAADGKAALOX15
SCHEMBL11685635 0.98 KMT2A (0.50) KMT2ASMN1; SMN2NAAADGKAALOX15
SCHEMBL1025347 0.98 KMT2A (0.50) KMT2ASMN1; SMN2NAAADGKAALOX15
SCHEMBL8990270 0.95 KMT2A (0.45) KMT2ASMN1; SMN2NAAADGKAALOX15
SCHEMBL2308841 0.95 KMT2A (0.45) KMT2ASMN1; SMN2NAAADGKAALOX15
SCHEMBL3252645 0.87 ALDH1A1 (0.43) KMT2ASMN1; SMN2ALOX15LMNAMEN1
SCHEMBL10483624 0.87 NAAA (0.47) KMT2ASMN1; SMN2NAAADGKAALOX15
SCHEMBL11801851 0.87 NAAA (0.44) KMT2ASMN1; SMN2NAAADGKAALOX15
SCHEMBL404170 0.79
SCHEMBL7117515 0.79 TSHR (0.44) KMT2ASMN1; SMN2NAAADGKALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220409526-A1 COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS RETINA FOUND OF THE SOUTHWEST (US) 2022-12-29 US claimed
US-20220409526-A1 COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS RETINA FOUND OF THE SOUTHWEST (US) 2022-12-29 US disclosed
CN-112741816-A Novel colon drug delivery system 江苏集萃新型药物制剂技术研究所有限公司 2021-05-04 CN disclosed
CN-111372950-A VEGFR-antibody light chain fusion proteins 免疫苏醒公司 2020-07-03 CN disclosed
CN-111214701-A Implants for localized drug delivery and methods of use thereof 加利福尼亚大学董事会 2020-06-02 CN disclosed
EP-2171021-B1 USE OF A CONDUCTIVITY IMPROVER IN A HYDROCARBON COMPOSITION INNOSPEC LTD (GB) 2020-04-01 EP disclosed
CN-106573133-B Implants for localized drug delivery and methods of use thereof 加利福尼亚大学董事会 2020-03-03 CN disclosed
EP-2102317-B1 ADDITIVE, FUEL COMPOSITION, METHOD AND USE INNOSPEC LTD (GB) 2018-10-17 EP disclosed
EP-1640438-B1 Improvements in Fuel Oils INFINEUM INT LTD (GB) 2017-08-30 EP disclosed
US-8961622-B2 Additives for improving the cold properties of fuel oils CLARIANT FINANCE (BVI) LIMITED (VG) 2015-02-24 US disclosed
EP-0721492-A1 ADDITIVES AND FUEL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1996-07-17 EP disclosed
WO-1996018707-A1 FUEL OIL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1996-06-20 WO disclosed
WO-1996018708-A1 FUEL OIL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1996-06-20 WO disclosed
WO-1996018706-A1 FUEL OIL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1996-06-20 WO disclosed
WO-1995033805-A1 FUEL OIL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1995-12-14 WO disclosed
WO-1995033021-A1 OIL ADDITIVES AND COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1995-12-07 WO disclosed
EP-0648258-A1 OIL ADDITIVES AND COMPOSITIONS. EXXON CHEMICAL PATENTS INC (US) 1995-04-19 EP disclosed
WO-1995003377-A1 ADDITIVES AND FUEL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1995-02-02 WO disclosed
WO-1994017159-A1 OIL AND FUEL OIL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1994-08-04 WO disclosed
WO-1994000386-A1 OIL ADDITIVES AND COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1994-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409526-A1 COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS PDE6C, STRA6, PDE6A KMT2A 3986/4885SMN1; SMN2 2532/4885NAAA 4388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.